
Quest Diagnostics guidance
$262.21+1.01%Close 16 Nov 2026 · Market value $28.35B
In its results release of 22 Oct 2026 (Q3 FY2026), Quest Diagnostics gave 5 forecasts in figures, among them revenue of $12.06B to $12.11B for FY2026. Over the last two years, results landed above the company's own last range 4 of 4 times, within it 0 and below it 0.
Read from the company's earnings releases and outlook updates of the last two years. Each forecast is shown with the sentence or table row it was read from; what a release does not state in figures is not shown.
Latest guidance given with Q3 FY2026 results, 22 Oct 2026
| Measure | Period | Guidance | As stated |
|---|
| Revenue | FY2026 | $12.06B to $12.11B | Full year 2026 revenues now expected to be between $12.065 billion and $12.105 billion |
|---|
| Revenue growth | FY2026 | +9.3% to +9.7% | Net revenues increase 9.3% - 9.7% |
|---|
| EPS growth · Adjusted | FY2026 | +15.4% | Third quarter reported diluted earnings per share ("EPS") of $2.78, up 28.7% from 2025; and adjusted diluted EPS of $3.00, up 15.4% from 2025 |
|---|
| EPS | FY2026 | $10.21 to $10.31 | Full year 2026 reported diluted EPS now expected to be between $10.21 and $10.31; and adjusted diluted EPS expected to be between $11.25 and $11.35 |
|---|
| Capital expenditures | FY2026 | $550M | Capital expenditures $550 million |
|---|
Source: the company's earnings release.
Guidance against results above 4 · within 0 · below 0
The last range given before each period closed, how it moved between releases, and the figure then filed. A measure the company defines itself, or one not comparable with the filed figure, has no verdict.
| Measure | Period | Last guidance | Revisions | Delivered | Result |
|---|
| Revenue | FY2026 | $12.06B to $12.11B | Raised 3 times | — | To come |
|---|
| Revenue growth | FY2026 | +9.3% to +9.7% | Raised 3 times | — | To come |
|---|
| EPS | FY2026 | $10.21 to $10.31 | Raised 3 times | — | To come |
|---|
| EPS · Adjusted | FY2026 | $10.50 to $10.70 | Given once | — | To come |
|---|
| EPS growth · Adjusted | FY2026 | +15.4% | Raised once, lowered once | — | To come |
|---|
| Capital expenditures | FY2026 | $550M | Unchanged | — | To come |
|---|
| Revenue | FY2025 | $10.96B to $11.00B | Raised twice | $11.04B | Above the range |
|---|
| Revenue growth | FY2025 | +11% to +11.4% | Raised twice | +11.78% | Above the range |
|---|
| Capital expenditures | FY2025 | $500M | Unchanged | $527M | Above the range |
|---|
| Revenue | FY2024 | $9.80B to $9.85B | Given once | $9.87B | Above the range |
|---|
| Revenue growth | FY2024 | +5.9% to +6.5% | Given once | +6.7% | Above the range |
|---|
| Capital expenditures | FY2024 | $420M | Given once | $425M | Above the range |
|---|
DGX in the terminal
Guidance said on earnings calls, every revision charted, and guidance set against the analysts' consensus.